Achieve Life Sciences (ACHV) to Release Earnings on Thursday

Achieve Life Sciences (NASDAQ:ACHV) will be releasing its earnings data after the market closes on Thursday, November 7th. Analysts expect Achieve Life Sciences to post earnings of ($0.26) per share for the quarter. Persons interested in participating in the company’s earnings conference call can do so using this link.

Achieve Life Sciences (NASDAQ:ACHV) last released its quarterly earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.03). During the same quarter in the previous year, the business earned ($0.43) earnings per share. On average, analysts expect Achieve Life Sciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Achieve Life Sciences Trading Up 0.6 %

ACHV traded up $0.03 during mid-day trading on Tuesday, reaching $4.77. The stock had a trading volume of 3,134 shares, compared to its average volume of 138,476. The stock has a market capitalization of $163.80 million, a P/E ratio of -4.27 and a beta of 1.57. The company has a debt-to-equity ratio of 0.21, a quick ratio of 4.56 and a current ratio of 4.56. The firm’s fifty day simple moving average is $4.66 and its two-hundred day simple moving average is $4.76. Achieve Life Sciences has a 52 week low of $3.03 and a 52 week high of $5.98.

Analysts Set New Price Targets

A number of research analysts have commented on ACHV shares. Oppenheimer reiterated an “outperform” rating and issued a $11.00 price objective on shares of Achieve Life Sciences in a research report on Thursday, August 15th. Raymond James began coverage on Achieve Life Sciences in a research report on Friday, September 27th. They issued a “strong-buy” rating and a $20.00 price objective on the stock.

Achieve Life Sciences Company Profile

Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.